Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | ERN1 | O75460 | 4/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | IL6 | P05231 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10845853 | 0.83 | CTSS (0.43) | CTSSCTSKP2RX7PIM1PIM3 | |
| SCHEMBL9340559 | 0.82 | TDP1 (0.38) | CTSSCTSKP2RX7PIM1PIM3 | |
| SCHEMBL25090393 | 0.80 | P2RX7 (0.44) | CTSSCTSKP2RX7NFKB1NOTUM | |
| SCHEMBL6853771 | 0.79 | NFKB1 (0.44) | CTSSPIM1PIM3NFKB1MEN1 | |
| SCHEMBL67207 | 0.79 | NFKB1 (0.57) | PIM1PIM3NFKB1MEN1LMNA | |
| SCHEMBL29417728 | 0.79 | NFKB1 (0.57) | PIM1PIM3NFKB1MEN1LMNA | |
| SCHEMBL17894487 | 0.78 | MRGPRX4 (0.47) | CTSSCTSKP2RX7KDM4ESMN1; SMN2 | |
| SCHEMBL3794351 | 0.78 | TDP1 (0.58) | MEN1LMNATHRBBLMKMT2A | |
| SCHEMBL1043059 | 0.78 | P2RX7 (0.57) | CTSSCTSKP2RX7TDP1NOTUM | |
| SCHEMBL622545 | 0.78 | ERN1 (0.44) | CTSSPIM1PIM3NFKB1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003200-A | P2X7 regulator | 詹森药业有限公司 | 2019-07-12 | — | — | CN | claimed |
| EP-3191492-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | claimed |
| CN-105209464-B | P2X7 modulators | 詹森药业有限公司 | 2019-01-01 | — | — | CN | claimed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | claimed |
| EP-0529400-A1 | 3-(2-Chloro-3-trifluoromethyl)-4-cyanopyrrole, as insecticides | BAYER AG (DE) | 1993-03-03 | — | — | EP | claimed |
| EP-0145334-A2 | Benzaldehyde derivative and process for its preparation | Pfizer Limited (GB) | 1985-06-19 | — | — | EP | claimed |
| JP-5194381-A | — | — | None | — | — | JP | disclosed |
| EP-4702005-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | Metabolon Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12338243-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-24 | — | — | US | disclosed |
| US-20250120927-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | METABOLON INC. | 2025-04-17 | — | — | US | disclosed |
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| WO-2024227056-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | METABOLON INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| EP-0145334-A2 | Benzaldehyde derivative and process for its preparation | Pfizer Limited (GB) | 1985-06-19 | — | — | EP | disclosed |
| EP-0125803-A2 | Pharmaceutically active dihydropyridines | FISONS plc (GB) | 1984-11-21 | — | — | EP | disclosed |
| EP-0116769-A1 | Dihydropyridines | Pfizer Limited (GB) | 1984-08-29 | — | — | EP | disclosed |
| US-4224340-A | Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds | WILLIAM H. RORER, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4214003-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4197314-A | WITH A DIPHENYL NITRONE | WILLIAM H. RORER, INC. (US) | 1980-04-08 | — | — | US | disclosed |
| US-4153722-A | ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE | WILLIAM H. RORER, INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247027-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | CTSS 2569/4885CTSK 1661/4885P2RX7 2/4885 |
| US-12338243-B2 | P2X7 modulators | P2RX7, P2RX4, P2RX1 | CTSS 2298/4885CTSK 1472/4885P2RX7 1/4885 |
| US-20250120927-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | CNDP2, DPP7, DPEP1 | CTSS 427/4885CTSK 1454/4885P2RX7 2232/4885 |
| US-20240116930-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | CTSS 2569/4885CTSK 1661/4885P2RX7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.